Malin Corporation PLC Poseida files for potential IPO (3035M)
January 07 2019 - 2:00AM
UK Regulatory
TIDM0Y71
RNS Number : 3035M
Malin Corporation PLC
07 January 2019
Malin Corporation plc
("Malin")
Poseida files for potential IPO on the NASDAQ Global Select
Market
Dublin-Ireland, 7 January 2019: Malin Corporation plc (ISE:MLC),
a company investing in highly innovative life sciences companies,
today notes that its investee company Poseida Therapeutics, Inc.
("Poseida"), a clinical-stage biotechnology company based in San
Diego, California, has filed a registration statement on Form S-1
("Registration Statement") with the U.S. Securities and Exchange
Commission (the "SEC") relating to a proposed initial public
offering ("IPO") in the United States of shares of Poseida's common
stock. Poseida has applied to list its common stock on The Nasdaq
Global Select Market under the symbol "PSTX". The number of shares
of common stock to be offered and the price range for the offering
have not yet been determined.
The Registration Statement relating to these securities has been
filed with the SEC but has not yet become effective. These
securities may not be sold, nor may offers to buy be accepted,
prior to the time the Registration Statement becomes effective.
The offering will be made only by means of a prospectus. A copy
of the preliminary prospectus, when available, may be obtained from
the SEC's EDGAR database and contains further information relating
to Poseida.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such
jurisdiction.
ENDS
For further information, please contact:
Malin
Jessica Bergin, Director of Investor Relations & External
Reporting
Tel: +353 (0)1 901 5700
investorrelations@malinplc.com
Consilium Strategic Communications (Financial PR)
Mary-Jane Elliott / Jonathan Birt
Tel: +44 (0)20 3709 5700
malin@consilium-comms.com
Powerscourt (Ireland PR)
Eavan Gannon
Tel: +353 87 236 5973
malin@powerscourt-group.com
Davy Corporate Finance (ESM Adviser)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
About Malin Corporation plc
Malin (ISE:MLC) is a company investing in highly innovative life
sciences companies. Its purpose is to create shareholder value
through the application of long-term capital and operational and
strategic expertise to a diverse range of global healthcare
businesses. Malin has a focus on innovative businesses underpinned
by exceptional science and works with its investee companies,
providing strategic and financial support to enable them to reach
their value potential. Malin is headquartered and domiciled in
Ireland and listed on Euronext Dublin. For more information visit
www.malinplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFQLLBKFFEBBE
(END) Dow Jones Newswires
January 07, 2019 02:00 ET (07:00 GMT)
Malin (LSE:0Y71)
Historical Stock Chart
From Apr 2024 to May 2024
Malin (LSE:0Y71)
Historical Stock Chart
From May 2023 to May 2024